The mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy

Journal of Virology

Volumn 87, Issue 12, 2013, Pages 7046-7053

  Ma, Xueying ^a   Xu, Ren Huan ^a   Roscoe, Felicia ^a   Whitbeck, J Charles ^b   Eisenberg, Roselyn J ^b   Cohen, Gary H ^b   Sigala, Luis J ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A33R; MONOCLONAL ANTIBODY B5R; MONOCLONAL ANTIBODY L1R; MONOCLONAL ANTIBODY VMC 14; MONOCLONAL ANTIBODY VMC 2; MONOCLONAL ANTIBODY VMC 78; MOUSE VIRUS PROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMET ASSAY; CONTROLLED STUDY; ECTROMELIA VIRUS; INFECTION CONTROL; INFECTION PREVENTION; MATURE VIRUS; MOUSE; MOUSEPOX; NONHUMAN; PRIORITY JOURNAL; THERAPY DELAY; VACCINATION; VIRION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS LOAD; VIRUS PARTICLE; VIRUS RELEASE; VIRUS TRANSMISSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CYTOSOL; ECTROMELIA VIRUS; ECTROMELIA, INFECTIOUS; IMMUNOGLOBULIN G; LIVER; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; VIRION;

ECTROMELIA VIRUS; MONKEYPOX VIRUS; MUS; POXVIRIDAE; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 84878529146     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03158-12     Document Type: Article

References (43)

1. Flint SJ, Enquist LW, Racaniello VR, Skalka AM. 2009. Principles of virology, 3rd ed. ASM Press, Washington, DC.
2. Virgin HW. 2007. Pathogenesis of viral infection, p 335-336. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed, vol 1. Lippincott Williams & Wilkins, Philadelphia, PA.
3. Chapman JL, Nichols DK, Martinez MJ, Raymond JW. 2010. Animal models of orthopoxvirus infection. Vet. Pathol. 47:852-870.
4. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi D, World Health Organization. 1988. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
5. Bray M. 2003. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res. 58:101-114.
6. Bray M, Wright ME. 2003. Progressive vaccinia. Clin. Infect. Dis. 36:766-774.
7. Cono J, Casey CG, Bell DM, Centers for Disease and Prevention. 2003. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm. Rep. 52(RR-4):1-28.
8. Esteban DJ, Buller RM. 2005. Ectromelia virus: the causative agent of mousepox. J. Gen. Virol. 86:2645-2659.
9. Fenner F. 1994. Mousepox (ectromelia), p 412. In Osterhaus A (ed), Virus infections of rodents and lagomorphs, vol 5. Elsevier Science, Amsterdam, Netherlands.
10. Wallace GD, Buller RM. 1985. Kinetics of ectromelia virus (mousepox) transmission and clinical response in C57BL/6j, BALB/cByj and AKR/J inbred mice. Lab. Anim. Sci. 35:41-46.
11. Blasco R, Moss B. 1991. Extracellular vaccinia virus formation and cellto-cell virus transmission are prevented by deletion of the gene encoding the 37,000-dalton outer envelope protein. J. Virol. 65:5910-5920.
12. Blasco R, Moss B. 1992. Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J. Virol. 66:4170-4179.
13. Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed). 2007. Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
14. Payne LG. 1980. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J. Gen. Virol. 50:89-100.
15. Smith GL, Vanderplasschen A, Law M. 2002. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83:2915-2931.
16. Buchman GW, Cohen ME, Xiao Y, Richardson-Harman N, Silvera P, DeTolla LJ, Davis HL, Eisenberg RJ, Cohen GH, Isaacs SN. 2010. A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine 28:6627-6636.
17. Fang M, Cheng H, Dai Z, Bu Z, Sigal LJ. 2006. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology 345:231-243.
18. Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. 2004. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78:10230-10237.
19. Golden JW, Hooper JW. 2011. The strategic use of novel smallpox vaccines in the post-eradication world. Expert Rev. Vaccines 10:1021-1035.
20. Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, Manischewitz J, King LR, Hryniewicz A, Trindade CJ, Hassett M, Tsai WP, Venzon D, Nalca A, Vaccari M, Silvera P, Bray M, Graham BS, Golding H, Hooper JW, Franchini G. 2006. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177:2552-2564.
21. Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL. 2000. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266:329-339.
22. Hooper JW, Custer DM, Thompson E. 2003. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306:181-195.
23. Hooper JW, Golden JW, Ferro AM, King AD. 2007. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 25:1814-1823.
24. Hooper JW, Thompson E, Wilhelmsen C, Zimmerman M, Ichou MA, Steffen SE, Schmaljohn CS, Schmaljohn AL, Jahrling PB. 2004. SmallpoxDNAvaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78:4433-4443.
25. Xiao Y, Aldaz-Carroll L, Ortiz AM, Whitbeck JC, Alexander E, Lou H, Davis HL, Braciale TJ, Eisenberg RJ, Cohen GH, Isaacs SN. 2007. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 25: 1214-1224.
26. Wittek R. 2006. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int. J. Infect. Dis. 10:193-201.
27. Xiao Y, Isaacs SN. 2010. Therapeutic vaccines and antibodies for treatment of orthopoxvirus infections. Viruses 2:2381-2403.
28. Lustig S, Maik-Rachline G, Paran N, Melamed S, Israely T, Erez N, Orr N, Reuveny S, Ordentlich A, Laub O, Shafferman A, Velan B. 2009. Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response. Vaccine 27:1691-1699.
29. Fang M, Sigal LJ. 2005. Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J. Immunol. 175:6829-6836.
30. Fang M, Sigal LJ. 2006. Direct CD28 costimulation Is required for CD8_ T cell-mediated resistance to an acute viral disease in a natural host. J. Immunol. 177:8027-8036.
31. Xu RH, Cohen M, Tang Y, Lazear E, Whitbeck JC, Eisenberg RJ, Cohen GH, Sigal LJ. 2008. The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. J. Exp. Med. 205:981-992.
32. Roscoe F, Xu RH, Sigal LJ. 2012. Characterization of ectromelia virus deficient in EVM036, the homolog of vaccinia virus F13L, and its application for the rapid generation of recombinant viruses. J. Virol. 86:13501-13507.
33. Aldaz-Carroll L, Whitbeck JC, Ponce de Leon M, Lou H, Pannell LK, Lebowitz J, Fogg C, White CL, Moss B, Cohen GH, Eisenberg RJ. 2005. Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology 341:59-71.
34. Xu RH, Rubio D, Roscoe F, Krouse TE, Truckenmiller ME, Norbury CC, Hudson PN, Damon IK, Alcami A, Sigal LJ. 2012. Antibody inhibition of a viral type 1 interferon decoy receptor cures a viral disease by restoring interferon signaling in the liver. PLoS Pathog. 8:e1002475. doi: 10.1371/journal.ppat.1002475.
35. Aldaz-Carroll L, Whitbeck JC, Ponce de Leon M, Lou H, Hirao L, Isaacs SN, Moss B, Eisenberg RJ, Cohen GH. 2005. Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J. Virol. 79:6260-6271.
36. Cohen ME, Xiao Y, Eisenberg RJ, Cohen GH, Isaacs SN. 2011. Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors. PLoS One 6:e20597. doi:10.1371/journal.pone .0020597.
37. Benhnia MR, McCausland MM, Laudenslager J, Granger SW, Rickert S, Koriazova L, Tahara T, Kubo RT, Kato S, Crotty S. 2009. Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. J. Virol. 83:12355-12367.
38. Lustig S, Fogg C, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. 2005. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J. Virol. 79:13454-13462.
39. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. 1994. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76:519-529.
40. Fang M, Orr MT, Spee P, Egebjerg T, Lanier LL, Sigal LJ. 2011. CD94 is essential for NK cell-mediated resistance to a lethal viral disease. Immunity 34:579-589.
41. Benhnia MR, McCausland MM, Moyron J, Laudenslager J, Granger S, Rickert S, Koriazova L, Kubo R, Kato S, Crotty S. 2009. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J. Virol. 83:1201-1215.
42. Vliegen I, Yang G, Hruby D, Jordan R, Neyts J. 2012. Deletion of the vaccinia virus F13L gene results in a highly attenuated virus that mounts a protective immune response against subsequent vaccinia virus challenge. Antiviral Res. 93:160-166.
43. Xu RH, Fang M, Klein-Szanto A, Sigal LJ. 2007. Memory CD8+ T cells are gatekeepers of the lymph node draining the site of viral infection. Proc. Natl. Acad. Sci. U. S. A. 104:10992-10997.